Provexis Regulatory News (PXS)

24 Jun 2005 08:00

Angle PLC24 June 2005 FOR IMMEDIATE RELEASE 24 June 2005 ANGLE plc ('ANGLE' or the 'Company') First day of Dealings for venture company Provexis plc on AIM ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce that its venture companyProvexis plc, the nutraceutical company which develops scientifically-proven,proprietary, functional foods, supplements and medical foods, announcescommencement of trading today in its ordinary shares on AIM under the tickersymbol: PSX.L. At the placing price of 5.6p per ordinary share, Provexis raised £5.9 million ofequity through an institutional placing of £3.8 million (before expenses) andthe conversion of £2.1 million of loans. On Admission and at the issue price themarket capitalisation was approximately £14 million. Following the PlacingANGLE owns 24.8% of Provexis plc. For further details please contact: ANGLE plc Andrew Newland, Chief Executive Tel: +44 (0)1483 295830 Dawson Buck, Deputy Chief Executive Buchanan Communications Richard Darby Tel: +44 (0)20 7466 5000 Suzanne Brocks James Strong Note to editors: ANGLE plc Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM(AGL.L); further information can be found on www.ANGLEplc.com Provexis plc Provexis is a nutraceutical business founded in 2000 as a joint venture with theRowett Institute, a leading human nutrition research centre and ANGLE, and is 1of the 8 venture companies developed under ANGLE's Progeny(R) programme to date. This information is provided by RNS The company news service from the London Stock Exchange